Is metabotropic glutamate receptor 5 upregulated in prefrontal cortex in fragile X syndrome?

Citation for published version:
Lohith, TG, Osterweil, EK, Fujita, M, Jenko, KJ, Bear, MF & Innis, RB 2013, 'Is metabotropic glutamate receptor 5 upregulated in prefrontal cortex in fragile X syndrome?' Molecular Autism, vol. 4, no. 1, pp. 15. DOI: 10.1186/2040-2392-4-15

Digital Object Identifier (DOI):
10.1186/2040-2392-4-15

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Molecular Autism

Publisher Rights Statement:
© 2013 Lohith et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Is metabotropic glutamate receptor 5 upregulated in prefrontal cortex in fragile X syndrome?

Talakad G Lohith1*, Emily K Osterweil2, Masahiro Fujita1, Kimberly J Jenko1, Mark F Bear2 and Robert B Innis1*

Abstract

Background: Fragile X syndrome (FXS) is a common inherited form of intellectual disability caused by loss of function of the fragile X mental retardation protein. Recent animal studies suggest that upregulated downstream signaling by metabotropic glutamate receptor 5 (mGluR5) might be an important mechanism for cognitive and behavioral abnormalities associated with FXS. However, mGluR5 density in human FXS remains unknown.

Methods: Receptor binding and protein expression were measured in the postmortem prefrontal cortex of 14 FXS patients or carriers and 17 age- and sex-matched control subjects without neurological disorders. In-vitro binding assays were performed using [3H]-labeled 3-methoxy-5-pyridin-2-ylethynylpyridine (MPEPy), a selective and high-affinity negative allosteric modulator of mGluR5, to measure receptor density and the radioligand's dissociation constant, which is inversely proportional to affinity. Immunoblotting was also performed, to measure mGluR5 protein expression.

Results: The mGluR5 density increased with marginal significance (+16%; \( P = 0.058 \)) in the prefrontal cortex of FXS patients or carriers compared with matched healthy controls. No significant change in dissociation constant (−4%; \( P = 0.293 \)) was observed. Immunoblotting found a significant elevation (+32%; \( P = 0.048 \)) in mGluR5 protein expression.

Conclusions: Both mGluR5 binding density and protein expression were increased in the brains of FXS patients or carriers, but only expression was significantly different, which could be because of the small sample size and moderate variability. Another important caveat is that the effects of psychotropic medications on mGluR5 expression are largely unknown. Future in-vivo measurement of mGluR5 with positron emission tomography might characterize the role of this receptor in the pathophysiology of FXS and facilitate trials of mGluR5-oriented treatments for this disorder.

Keywords: Fragile X mental retardation protein, Fragile X syndrome, Glutamate receptor, mGluR5, Receptor density, Receptor expression

Background

Fragile X syndrome (FXS), the most common cause of inherited intellectual disability, is associated with multiple cognitive, behavioral, and neuropsychiatric abnormalities [1]. The disorder is caused by expansion of the CGG trinucleotide repeat in the 5′ untranslated region of the fragile X mental retardation 1 (FMR1) gene located at the distal end of the long arm of the X chromosome. The length of repeat expansion determines the expression of FXS disorder: alleles containing ≤44 repeats are considered ‘normal’, those containing between 44 and 54 repeats form a ‘gray zone’, those containing between 55 and 200 repeats are ‘premutation carriers’, and alleles with ≥200 repeats are ‘full mutations’ [2]. Only the full mutation leads to hypermethylation of the FMR1 promoter and consequent transcriptional silencing of the FMR1 gene that encodes fragile X mental retardation protein (FMRP) [3]. FMRP is a cytoplasmic RNA-binding protein known to repress the translation of specific messenger RNAs at neuronal synapses, thereby regulating expression of various synaptic proteins [4,5]. FMRP thus plays a major role in synaptic signal transduction, and its loss dysregulates neuronal

* Correspondence: lohithtg@mail.nih.gov; innisr@mail.nih.gov
1Molecular Imaging Branch, National Institute of Mental Health, 10 Center Drive, Bethesda, MD 20892-1026, USA
Full list of author information is available at the end of the article

© 2013 Lohith et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
signaling pathways. One of the key signaling pathways believed to be dysregulated in FXS as the result of a loss of FMRP is mediated by metabotropic glutamate receptors (mGluRs), particularly subtype 5 (mGluR5). Studies have demonstrated that dysregulated mGluR5 signaling results in uncontrolled activation of synaptic protein synthesis, owing to the loss of normal repressor action of FMRP on protein synthesis [6,7].

Recent studies using various animal models of FXS have suggested that many features of the FXS phenotype, including behavioral abnormalities, cognitive deficits, and altered dendritic spines, may be attributable to exaggerated mGluR5 signaling. Some studies that sought to suppress mGluR5 signaling by genetic knockdown or by using negative allosteric modulators of mGluR5, such as 2-methyl-6-(phenylethynyl)-pyridine (MPEP), corrected most of these phenotypic features in mouse models of FXS [8,9]. Although evidence from rodent studies suggests that mGluR5 signaling is increased in FXS, mGluR5 density has yet to be examined in the postmortem brain tissue of individuals with FXS. Answering this question is important because measuring mGluR5 levels could allow categorization of FXS patient subgroups based on receptor density and, relatedly, help identify those FXS patients who might be promising candidates for treatment with mGluR5 allosteric modulators.

To determine whether mGluR5 levels are altered in FXS, we measured mGluR5 receptor density via radioligand binding assays, and expression levels via Western blotting. These measures were ascertained in the postmortem brain tissue of FXS patients and premutation carriers, and compared with measures ascertained in age- and sex-matched healthy controls.

Methods

Human postmortem tissues

Postmortem human brain tissue from the prefrontal or frontal cortex was provided by the National Institute of Child Health & Human Development Brain and Tissue Bank for Developmental Disorders, University of Maryland, Baltimore, MD, USA, and by the Hagerman Laboratory, Department of Biochemistry and Molecular Medicine, University of California, Davis, CA, USA. As per US regulation 45 CFR 46, these postmortem specimens from deceased subjects were exempted by the Office of Human Subjects for ethical approval and did not need subject consent for use in the study. Tissue samples were available for 14 white male FXS patients or carriers, of which one had fragile X-associated tremor ataxia syndrome (FXTAS) and 17 white male healthy controls; the demographic characteristics of the samples are presented in Table 1. The FXS patients or carrier samples and the control samples were matched for age and postmortem interval; other demographic differences were considered insignificant for this study. Medication status before death was not available for many of the samples. Because only four samples from FXS carriers were available, those four samples were pooled with FXS patient samples for analysis purposes.

Tissue preparation

Tissue samples were homogenized using a mortar and pestle in fresh ice-cold, 50 mM Tris–HCl buffer (1:10 w/v) completing 3 × 10 passes with cooling on ice between homogenizations. Homogenates were centrifuged at 20,000 g and 4°C for 25 minutes, followed by removal of the supernatant. Pellets were then resuspended in fresh ice-cold 50 mM Tris–HCl buffer and centrifuged again at the same settings. Pellets were resuspended in fresh ice-cold 50 mM Tris–HCl buffer at a protein concentration of approximately 1 mg of protein/mL. Aliquots were stored in a freezer at −80°C until further use. Protein concentrations were determined using the Bradford protein assay (Bio-Rad, Hercules, CA), and absorption was read at 595 nm.

Competition binding assays

An ethanolic solution of [3H]-labeled 3-methoxy-5-pyridin-2-ylethynlypyridine (MPEPy), a selective and high-affinity negative allosteric modulator of mGluR5, was purchased from American Radiolabeled Chemicals Inc. (St. Louis, MO) at a specific activity of 2.96 TBq/mmol and a radiochemical purity of 99%. Nonradioactive MPEPy was purchased from Tocris Bioscience (Ellisville, MO). The chemical purity of nonradioactive MPEPy was 100%, as determined by high performance liquid chromatography.

The specific binding, mGluR5 receptor density (Bmax), and the radioligand’s dissociation constant (Kd), which is inversely proportional to affinity, were determined in human brain tissue homogenates using standard, steady-state homologous competition binding assays [10,11] using 0.48 nM [3H]MPEPy and concentrations of unlabeled MPEPy ranging from 0.1 nM to 1 μM. Nonspecific binding was determined in the presence of 10 μM of unlabeled ligand. Assays were performed for each tissue sample in triplicate with 0.1 mg protein per assay tube in a final volume of 300 μL, and incubated with shaking for 2 hours at room temperature. After incubation, assay reaction was terminated by filtration using a cell harvester (Model# M-48T; Brandel Inc., Gaithersburg, MD) through Whatman GF/B filters (Brandel Inc., Gaithersburg, MD) followed by 3 × 1 mL washes with ice-cold 50 mM Tris–HCl buffer. Whatman GF/B filters were preincubated with 0.5% polyethyleneimine for 30 minutes before filtration. Scintillation fluid (Ultima Gold, PerkinElmer, Downers Grove, IL) was added at 4 mL/vial; vials were counted on a Tri-Carb 3100TR...
liquid scintillation counter (PerkinElmer, Downers Grove, IL) for five minutes each.

**Western blotting**

Cortical tissue samples were boiled in Laemmli sample buffer and 20 μg of total protein resolved on 10% SDS PAGE gels. All gels were loaded with an equal number of control and FXS samples, and these were loaded in an alternating fashion, to distribute both genotypes equally across the gel. Gels were transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA) and stained for total protein using the Memcode staining kit (Pierce Biotechnology, Rockford, IL, USA). Immunoblotting was performed using 2 μg/mL primary antibody to mGluR5 (Neuromics, Northfield, MN, USA), HRP-conjugated secondary antibody (GE Healthcare, Milwaukee, WI, USA), and ECL plus (GE Healthcare, Milwaukee, WI, USA).

**Table 1 Demographic data for human brain tissue samples**

| Case | Diagnosis | CGG repeats | Age (years) | Postmortem interval (hours) | Cause of death | Central nervous system drug use |
|------|-----------|-------------|-------------|-----------------------------|----------------|-------------------------------|
| UMB-1421 | Fragile X | 563<sup>2</sup>, 297<sup>2</sup> | 69 | 17 | Cancer | NA |
| UMB-1938 | Fragile X | NA | 62 | 26 | Hypertensive cardiovascular disease | NA |
| UMB-4751 | Fragile X carrier | 88 | 21 | 5 | Pulmonary edema or pneumonia | Antiepileptics |
| UMB-4806 | Fragile X | NA | 9 | 22 | Cardiac arrest | Clonidine |
| UMB-5006 | Fragile X carrier | 150 | 85 | 5 | Complication of disorder | NA |
| UMB-5319 | Fragile X | NA | 71 | 17 | Complication of disorder | NA |
| UMB-4664 | Fragile X carrier | 100 | 71 | 3 | Complication of disorder | NA |
| UMB-5212 | Fragile X carrier (FXTAS) | NA | 80 | 12 | Complication of disorder | NA |
| 1031-08-GP | Fragile X | 436 | 57 | 20 | Food choking | Antipsychotics |
| JS-03 | Fragile X | NA | 25 | 16 | NA | NA |
| 1005-06-CB/XX | Fragile X | NA | 55 | - | NA | NA |
| 1018-10-RH | Fragile X | NA | 60 | 55 | NA | NA |
| 1031-09-LZ | Fragile X | 429<sup>2</sup>, 340 – 440<sup>2</sup> | 64 | 12 | Cancer | None |
| 1033-08-WS | Fragile X | > 339<sup>2</sup> | 78 | 18 | Chronic obstructive pulmonary disease or cardiac block | Antiepileptics |
| UMB-1442 | Healthy | NA | 22 | 7 | Multiple injuries | NA |
| UMB-5082 | Healthy | NA | 68 | 19 | Arteriosclerotic cardiovascular disease | None |
| UMB-5123 | Healthy | NA | 61 | 24 | Arteriosclerotic cardiovascular disease | NA |
| UMB-1103 | Healthy | NA | 21 | 7 | Accident, multiple injuries | NA |
| UMB-1674 | Healthy | NA | 8 | 36 | Hyperthermia and drowning | NA |
| UMB-5182 | Healthy | NA | 86 | 23 | Hypertensive cardiovascular disease | NA |
| UMB-1104 | Healthy | NA | 35 | 12 | Accident, multiple injuries | Alcohol |
| UMB-4593 | Healthy | NA | 33 | 8 | Cardiac arrhythmia | NA |
| UMB-4598 | Healthy | NA | 45 | 6 | Dilated cardiomyopathy | NA |
| UMB-4735 | Healthy | NA | 73 | 21 | Chronic obstructive pulmonary disease | NA |
| UMB-5171 | Healthy | NA | 79 | 5 | Chronic obstructive pulmonary disease or peripheral vascular disease | None |
| UMB-1039 | Healthy | NA | 49 | 9 | Accident, multiple injuries | NA |
| UMB-1227 | Healthy | NA | 52 | 16 | Pulmonary embolism | NA |
| UMB-1228 | Healthy | NA | 47 | 13 | Arteriosclerotic cardiovascular disease | NA |
| UMB-1570 | Healthy | NA | 48 | 14 | Arteriosclerotic cardiovascular disease | NA |
| UMB-1907 | Healthy | NA | 54 | 17 | Accident, multiple injuries | NA |
| UMB-4915 | Healthy | NA | 49 | 5 | Arteriosclerotic cardiovascular disease | NA |

| Number of subjects (n) | Diagnosis | Age (years)<sup>2</sup> | Postmortem interval (hours)<sup>2</sup> |
|-----------------------|-----------|-------------------------|-----------------------------------------|
| 14 | Fragile X (n = 10) or carrier (n = 4) | 58, 9 to 85 | 17, 3 to 55 |
| 17 | Healthy | 49, 8 to 86 | 14, 5 to 36 |

FXTAS, fragile X-associated tremor ataxia syndrome; NA, not available; <sup>a</sup>all brain tissues were from white male subjects and from prefrontal cortex except for case 1033-08-WS, which was from frontal cortex; <sup>b</sup>at time of death; <sup>c</sup>no significant difference was found in age (<i>t</i> = 1.11, <i>df</i> = 29, <i>P</i> = 0.276) or postmortem interval (<i>t</i> = 0.83, <i>df</i> = 28, <i>P</i> = 0.411) between FXS patients or carriers and healthy controls; <sup;d</sup>hypermethylated repeats; <sup>e</sup>unmethylated repeats.

Lohith et al. Molecular Autism 2013, 4:15 http://www.molecularautism.com/content/4/1/15
Data and statistical analysis
To determine the receptor density and dissociation constant, specific binding from triplicate measurements of each sample of competition assay data was analyzed using the iterative nonlinear regression curve-fitting software in GraphPad Prism software (version 5.0, GraphPad Software Inc., San Diego, CA, USA). The equation for specific binding is:

\[
\text{Specific binding} = \frac{B_{\text{max}} [\text{Hot}]}{[\text{Hot}] + [\text{Cold}] + K_D}
\]

[Hot] and [Cold] represents [3H]MPEPy and unlabeled MPEPy respectively. One-site and two-site homologous competition models were fitted to the data using the least-squares algorithm, and the model was selected using the F test. The null hypothesis, that the data would fit a one-site model, was rejected if the P value was less than 0.05. The two-site model was rejected if the receptor density from low-affinity sites had inappropriately high values [12].

The level of mGluR5 expression was measured by densitometry using Quantity One software (Bio-Rad), and normalized to a one-dimensional line-scan of the total protein Memcode signal in the same lane. To correct for blot-to-blot variance, each signal was normalized to the average signal of all lanes on the same blot. Outliers were removed from data analysis if the final values fell outside plus or minus two standard deviations. All gels were loaded and analyzed blind to genotype and treatment.

Data were analyzed for normal distribution by the Shapiro-Wilk normality test using SPSS Statistics (Version 17.0, SPSS Inc., Chicago, IL, USA). If the samples were normally distributed, statistical comparisons were performed using the two-tailed unpaired Student’s t-test; otherwise, the nonparametric Mann–Whitney test was performed to obtain P values. Correlations between receptor density and expression levels were examined with Pearson’s correlation test. A P value of less than 0.05 was considered statistically significant, between 0.05 to 0.1 as marginally significant and more than 0.1 as nonsignificant.

Results
Density and expression levels of mGluR5 were marginally higher in prefrontal cortex of FXS patients or carriers
The binding curves generated from homologous competition binding assays performed on postmortem prefrontal cortex samples of 14 FXS patients or carriers and 17 matched controls demonstrated that at low concentrations of unlabeled MPEPy, specifically bound [3H] MPEPy was higher in prefrontal cortex samples from the FXS group than the control group (Figure 1A). The binding curves best fit the one-site homologous model, which was used to determine binding measures. The mGluR5 receptor density increased with marginal significance (+16%; t = 1.97, df = 29, P = 0.058) for FXS patients or carriers, as compared with control samples (Figure 1B, Table 2). The dissociation constant did not differ significantly between groups (−4%; Mann–Whitney U = 92.0, P = 0.293). In addition, Western blot analyses consistently revealed a stronger mGluR5 band corresponding to a molecular mass of 150 kDa in FXS patients or carriers (Figure 1C), with the average mGluR5: total protein ratio higher and significant (+32%; t = 2.07, df = 28, P = 0.048) for FXS patients or carriers (mean = 1.32, standard deviation = 0.16) than for control samples (mean = 1.0, standard deviation = 0.05; Figure 1D). When the four FXS carriers were excluded from the analysis, both mGluR5 density and expression were higher (+17%; t = 1.88, df = 25, P = 0.071 and +25%; t = 1.51, df = 24, P = 0.147, respectively), but only mGluR5 density was marginally significant between FXS patients and control samples.

Binding assay and immunoblot data correlated positively but were independent of age or postmortem interval
Pearson’s correlation analysis showed a significant positive correlation (r = 0.43; P = 0.018) between mGluR5 density values and expression levels from corresponding tissue samples (Figure 2). In addition, individually the correlation was positive and similar but not significant for both FXS patients or carriers (r = 0.42; P = 0.136) and control (r = 0.41; P = 0.114) subjects. However, receptor density and mGluR5 expression levels from both FXS patients or carriers and control subjects did not significantly correlate with age (mGluR5 density: r = −0.36, P = 0.203 and r = 0.13, P = 0.609; mGluR5 expression: r = −0.35, P = 0.216 and r = 0.17, P = 0.539 for FXS and controls, respectively) or postmortem interval (mGluR5 density: r = 0.26, P = 0.395 and r = −0.30, P = 0.249; mGluR5 expression: r = 0.23, P = 0.444 and r = 0.17, P = 0.525 for FXS and controls, respectively), indicating that mGluR5 receptor density and expression level occurred independently of age or postmortem interval.

Discussion
Using in-vitro radioligand binding assays and Western blotting, we found a marginally significant increase in mGluR5 receptor density and a statistically significant increase in mGluR5 expression from the postmortem prefrontal cortex of FXS patients or carriers, compared with age- and sex-matched controls without neurological disorders. Highly significant differences in mGluR5 density could not be measured, mainly because of the limited availability of postmortem human brain tissues from FXS patients; nevertheless, the results raise the
important question of whether mGluR5 density is indeed increased in the brains of individuals with FXS. While numerous preclinical studies have linked increased mGluR5 receptor signaling to various syndromic features of FXS [6,7], this study is the first to measure mGluR5 receptor density or expression levels directly in the human brain of individuals with FXS or carriers. It is important to note, however, that several reports have described changes in mGluR5 expression in patients with autism or in FXS model mice [13-15].

Notably, FXS is the most common single-gene cause of autism, accounting for 2 to 6% of all cases of autism, and numerous studies suggest that similar sets of proteins are dysregulated in both autism and FXS, including mGluR5 [14,15]. For instance, Fatemi and colleagues [13] recently reported a statistically significant increase in mGluR5 protein levels in postmortem tissue samples from the superior frontal cortex of autistic children, a finding that was not significant in autistic adults. Interestingly, the same study also found significantly lower levels of FMRP in autistic adults, despite the fact that no records indicated that any of the individuals were tested for or diagnosed with FXS. Considering that autism and FXS are intertwined at the molecular level [15], the findings of the autism study are in agreement with the significantly increased mGluR5 expression observed in the present study in human prefrontal cortex of individuals with FXS.

**Table 2 Binding parameters from homologous competition binding assays**

| Binding parameters | Healthy (n=17) | Fragile X (n=14) | % change | P value |
|-------------------|--------------|-----------------|---------|--------|
| Receptor density  | 1410 ± 421   | 1683 ± 372      | 16      | 0.058  |
| (fmol/mg protein) |              |                 |         |        |
| Dissociation constant (nM) | 106 ± 4.0   | 102 ± 1.6       | -4      | 0.29b  |
| Binding potential (receptor density/dissociation constant) | 14 ± 5    | 17 ± 4           | 17      | 0.092  |

*aValues represent mean ± standard deviation; *b*P value determined from nonparametric Mann–Whitney test.
Reports of mGluR5 expression levels in brain samples from animal models of FXS are limited. Giuffrida and colleagues [16] recently found reduced mGluR5 expression in the detergent insoluble fraction of synaptic plasma membranes isolated from forebrains of Fmr1 knockout mice compared with wild-type mice; however, the mRNA and total mGluR5 protein expression in total membrane protein preparation were comparable between the two mouse groups. The study attributed the altered mGluR5 distribution to a complex interaction with Homer scaffolding proteins. Another study found that mGluR5 levels were significantly reduced in the lateral geniculate nucleus of Fmr1 KO mice [17]. In the Fmr1 KO hippocampus, however, Western blot analysis revealed no difference in mGluR5 protein expression [8]. In contrast to these reports, our results indicated significantly elevated expression of mGluR5 in human prefrontal cortex samples of FXS patients or carriers compared with healthy controls. This discrepancy might be due to several key factors, including differences between species, between the brain regions studied, and between experimental procedures.

Presently, we can only speculate about the mechanisms that might explain the increased mGluR5 levels observed in prefrontal cortex of FXS patients or carriers. The absence of FMRP in FXS has been implicated for both decreases and increases of different mRNA pools, owing to translational repression or activation of diverse mRNAs [5]. Although FMRP is not believed to be directly associated with Grm5 mRNA, its association with other mRNAs may indirectly upregulate mGluR5 levels [18]. However, overexpression of mGluR5 secondary to absence of FMRP may lead to reduced 2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid/N-methyl-D-aspartate receptors as well as alterations in several other signaling molecules; thus, FXS is currently considered a disease of dysregulated neuronal signaling [5].

Preclinical studies in FXS model mice suggest that synaptic protein synthesis is dysregulated by hypersensitivity to mGluR5 signaling in FXS. Indeed, reducing mGluR5 signaling by genetic knockdown or by administering mGluR5 negative allosteric modulators, such as MPEP, improved cognitive and behavioral measures in a mouse model of FXS [8,9]. Negative allosteric modulators of mGluR5 are presently being considered as potential treatments for FXS. In a pilot, open-label, single-dose, Phase I study with fenobam, a negative allosteric modulator of mGluR5 comparable to MPEP, 9 of 12 subjects exhibited calmed behavior within one hour of dosing, and 6 of 12 subjects had improved prepulse inhibition [19]. Another trial administered AFQ056, an mGluR5 negative allosteric modulator, for several weeks. Although the overall therapeutic efficacy in FXS was negative, a post-hoc analysis found significant therapeutic efficacy in 7 patients who had full FMR1 promoter methylation, but no response in 18 patients with partial promoter methylation [5,20]. Full methylation would be expected to cause complete silencing of the FMR1 gene with minimal expression of FMRP (comparable to the mouse KO model), whereas partial methylation would be associated with variable FMRP levels; this could perhaps affect the degree of mGluR5 hyperactivation and, thus, treatment response. Future treatment trials are likely to prospectively separate patients with and without hypermethylation of the FMR1 gene.

This study was associated with several limitations. First, the increased mGluR5 binding and expression observed in human prefrontal cortex samples from individuals with FXS patients or carriers might not reflect actual disease status; instead, it could result from treatment with antipsychotic medications. FXS patients are commonly treated with antipsychotic drugs in childhood and early adulthood, though usually not in late adulthood [21]. Medication status, which might have helped elucidate this issue, was not available for most of these tissue samples. Nevertheless, one study of rats chronically treated with the antipsychotic drugs haloperidol or risperidone found that mGluR5 expression in the frontal cortex was not altered, although significant changes were observed in subcortical regions, such as the caudate nucleus [22]. Second, tissue samples were only obtained from white male subjects. Thus, the presence of any potential sex-related or ethnic variation in mGluR5 binding or expression cannot be ruled out. The mutation...
responsible for FXS is known to affect men and women at equal rates, but owing to lyonization or X chromosome inactivation, FMRP levels are higher in women, with commensurately fewer and less severe physical, cognitive, and behavioral phenotypes [1]. Third, most tissue samples were from full mutation cases of FXS; only four samples were from FXS carriers. When FXS carrier samples were excluded from the analysis, both mGluR5 density and expression were higher, but only mGluR5 density was marginally significant between FXS and control samples. Unlike FXS patients with full mutation, premutation carriers are known to express low levels of functional FMRP. However, the carriers are known to have increased transcription of FMR1 mRNA, causing RNA toxicity by sequestering several proteins to form intracellular inclusion bodies [2]. These inclusion bodies have been found to contain several RNA-binding proteins, such as hnRNP2/B1, CUGBP1 and Sam68 [23,24]. Currently, it is not known whether RNA toxicity in carriers is associated with sequestration of receptor protein, such as mGluR5. Thus, the current finding of mGluR5 density or expression warrants further study in a greater number of subjects who are only FXS full mutation or FXS carriers. Furthermore, for most samples, neither information on the number of CGG repeats nor the methylation status in the FMR1 gene was available. The availability of this information would have allowed us to assess the correlation between methylation or CGG repeats and mGluR5 binding or expression, given that epigenetic modification of the FMR1 gene has been implicated in differential therapeutic response to mGluR5 antagonists in individuals with FXS [20]. Finally, owing to the limited availability of tissue samples, we were only able to evaluate mGluR5 measures in the prefrontal cortex of humans; other subcortical regions known to contribute to the various cognitive and psychomotor effects observed in FXS (for example, hippocampus, amygdala, and cerebellum) might have yielded different mGluR5 measures.

Despite these limitations, the marginally increased mGluR5 receptor density and expression observed in this study in individuals with FXS provide a strong rationale for measuring mGluR5 in living patients using positron emission tomography (PET) [25,26]. Such studies could address many questions raised in the postmortem study. First, PET could determine whether increased mGluR5 binding is present in live subjects and in all brain areas, including the prefrontal cortex. However, PET typically does not separately measure receptor density ($B_{\text{max}}$) and affinity ($1/K_D$). Instead, PET uses low tracer doses of the radioligand, which measures the product of these two variables, called the binding potential ($BP = B_{\text{max}}/K_D$). In our postmortem study, both BP and $B_{\text{max}}$ were increased (16% and 17%, respectively) with marginal statistical significance ($P = 0.058$ and $0.092$, respectively) for FXS patients compared with controls (Table 2). Even after excluding four FXS carriers, both BP and $B_{\text{max}}$ were increased (17% and 19%, respectively) with marginal statistical significance ($P = 0.071$ and 0.094, respectively) for FXS patients compared with controls. Because PET can only measure BP, based on 80% power and two-tailed $P < 0.05$, the required sample size for PET to detect a significant elevation in BP in the prefrontal cortex of FXS patients would be approximately 45 subjects. Second, the records from the postmortem samples contained inadequate information about prior drug treatment, which may have upregulated mGluR5. By selecting live, unmedicated subjects, PET imaging can more directly assess the possible confound of concomitant medications. Third, baseline mGluR5 levels could be correlated to any response to treatment with mGluR5 negative allosteric modulators. For example, would those subjects with the highest elevation of mGluR5 have the greatest response to this antagonist treatment?

**Conclusions**

This study was the first to identify upregulation of mGluR5 density and expression in the prefrontal cortex of FXS patients or carriers compared to an age- and sex-matched control group. This is consistent with several studies in FXS model mice that postulate that the syndromic features of FXS are caused by an upregulated mGluR5 signaling pathway. Although the sample size was relatively small and the results could be secondary to prior medication treatment, these initial findings provide strong rationale for measuring mGluR5 in live patients using PET. Such in-vivo studies could measure mGluR5 in all brain regions; the results could also be correlated with treatment response to mGluR5 negative allosteric modulators.

**Abbreviations**

BP: Binding potential; FMR1: Fragile X mental retardation 1; FMRP: Fragile X mental retardation protein; FX: Fragile X syndrome; FXAS: Fragile X-associated tremor ataxia syndrome; HPLC: High-performance liquid chromatography; KO: Knockout; mGluR: Metabotropic glutamate receptor; mGluR5: Metabotropic glutamate receptor type 5; MPEP: 2-methyl-6-(phenylethynyl)-pyridine; MPEPy: 3-methoxy-5-pyridin-2-ylethynylpyridine; PET: Positron emission tomography.

**Competing interests**

MF declares a financial interest in Seaside Therapeutics. TGL, EKO, MF, and KJJ report no biomedical financial interests. The authors declare that they have no competing interests.

**Authors’ contributions**

TGL participated in the study design, performed homogenate binding assays and statistical analysis, and drafted the manuscript. EKO carried out immunoblotting and statistical analysis and drafted the manuscript. KJJ participated in study design and homogenate binding assays. MF, RBI, and MF conceived the study, participated in its design and coordination and
helped to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgements
This study was partly supported by the Intramural Research Program of the National Institute of Mental Health, National Institutes of Health (IRP-NIMH-NI). We thank Dr. Paul J. Hagerman, Professor of the Department of Biochemistry and Molecular Medicine, University of California Davis School of Medicine, USA for kindly providing the human tissue samples. Human tissue was also obtained from the National Institute of Child Health & Development Brain and Tissue Bank for Developmental Disorders at the University of Maryland, Baltimore, MD. Ioline Henter (NIMH) provided valuable editorial assistance.

Author details
1 Molecular Imaging Branch, National Institute of Mental Health, 10 Center Drive, Bethesda, MD 20892-1026, USA. 2 Department of Brain and Cognitive Sciences, Howard Hughes Medical Institute, The Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

References
Published: 24 May 2013
Received: 22 February 2013 Accepted: 8 May 2013

1. Gallagher A, Hallihan B: Fragile X-associated disorders: a clinical overview. J Neurol 2012, 259:401–413.
2. Kim M, Cerman S: Fragile X mental retardation protein: past, present and future. Curr Protein Pept Sci 2012, 13:358–371.
3. Pieretti M, Zhang FP, Fu YH, Warren ST, Oostra BA, Caskey CT, Nelson DL: Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 1991, 66:817–822.
4. Li Z, Zhang Y, Xu L, Wilkinson KD, Warren ST, Feng Y: The fragile X mental retardation protein inhibits translation involving with mRNA. Nucleic Acids Res 2001, 29:2276–2283.
5. Gross C, Berry-Kravis EM, Bassell GJ: Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond. Neuropsychopharmacology 2012, 37:178–195.
6. Bear MF, Huber KM, Warren ST: The mGluR theory of fragile X mental retardation. Trends Neurosci 2004, 27:370–377.
7. Huber KM, Gallagher SM, Warren ST, Bear MF: Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci USA 2002, 99:7746–7750.
8. Dolen G, Osterweil E, Rao BS, Smith GB, Auerbach BD, Chattaraj S, Bear MF: Correction of fragile X syndrome in mice. Neuron 2007, 56:955–962.
9. Yao Q, Ramnal M, Tranfaglia M, Bauchwitz RP: Suppression of two major fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropsychopharmacology 2005, 49:1053–1066.
10. Bigott-Hennikens HM, Dannoon S, Lewis MR, Jurisins SS: In vitro receptor binding assays: general methods and considerations. Q J Nucl Med Mol Imaging 2008, 52:245–253.
11. Bylund DB, Toews ML: Radioligand binding methods for membane preparations and intact cells. Methods Mol Biol 2011, 746:135–164.
12. Analyzing Data with GraphPad Prism. http://graphpad.com/manuals/analyzingdata.pdf.
13. Fatemi SH, Folsom TD: Dysregulation of fragile X mental retardation protein and metabotropic glutamate receptor 5 in superior frontal cortex of individuals with autism: a postmortem brain study. Mol Autism 2011, 2:6.
14. Hagerman R, Au J, Hagerman P: FMR1 premutation and full mutation molecular mechanisms related to autism. J Neurodev Disord 2011, 3:211–224.
15. Hagerman R, Hoem G, Hagerman P: Fragile X and autism: intertwined at the molecular level leading to targeted treatments. Mol Autism 2010, 1:12.
16. Giuffrida R, Musumeci S, D’Antoni S, Bonaccorsi CM, Giuffrida-Stella AM, Oostra BA, Catania MV: A reduced number of metabotropic glutamate subtype 5 receptors are associated with constitutive homer proteins in a mouse model of fragile X syndrome. J Neurosci 2005, 25:8908–8916.
17. Govindaaish G, Venkitaramani DV, Chaki S, Cox CL: Down regulation of mGluR-dependent gabaergic signaling in fragile X syndrome. In Proceedings: Neuroscience 2011. Washington, DC: Society for Neuroscience; 2011:774.06.P4.
18. Brown V, Jin P, Cerman S, Darnell JC, O’Donnell WT, Tenenbaum SA, Jin X, Feng Y, Wilkinson KD, Keene JD, Darnell RB, Warren ST: Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell 2001, 107:477–487.
19. Berry-Kravis E, Hessl D, Coffey S, Hervey C, Schneider A, Yuhas J, Hutchinson J, Snape M, Tranfaglia M, Nguyen DV, Hagerman R: A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet 2009, 46:266–271.
20. Jacquemont S, des Portes V, Curie A, Torrioli MG, Berry-Kravis E, Hagerman RJ, Ramos FJ, Cornish K, He Y, Paulding C, Neri G, Chen F, Hadijkhan N, Martinet D, Meyer J, Beckmann JS, Delange K, Brun A, Bussy G, Gasparini F, Hise T, Fleesser A, Branson J, Bilge B, Johns D, Gomez-Mancilla B: Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med 2011, 3:54ra61.
21. Hagerman RJ, Berry-Kravis E, Kaufmann WE, Ono MY, Tartaglia N, Lachiewicz A, Kronk R, Delahunty C, Hessl D, Visootsak J, Pickler J, Gane L, Tranfaglia M: Advances in the treatment of fragile X syndrome. Pediatrics 2009, 123:378–390.
22. Ghose S, Gleason K, Potts B, Lewis K, Tamminger C: GRM 5 in the caudate nucleus in schizophrenia. In Proceedings: Neuroscience 2009. Chicago, IL: Society for Neuroscience; 2009:340.3/N24.
23. Siller C, Rau F, Liu Y, Tassone F, Hukema RK, Gartonni R, Schneider A, Richard S, Willensen R, Elliott DJ, Hagerman PJ, Charlet-Berguerand N: Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients. MBIO 2010, 29:1248–1261.
24. Sofola DA, Jin P, Qin Y, Duan R, Liu H, De Haro M, Nelson DL, Botas J: RNA-binding proteins hnrNP A2/B1 and CUGBP1 suppress fragile X CGG premutation repeat-induced neurodegeneration in a Drosophila model of FXTAS. Neuron 2007, 55:565–571.
25. Annimamye SM, Trever V, Streffer J, Wyss MT, Schmidt M, Blaurock M, Hintemans S, Auberson Y, Gasparini F, Fischer UC, Buck A: Human PET studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688. J Nucl Med 2007, 48:247–252.
26. Brown AK, Kimura Y, Zoghbi SS, Simeon FG, Liow JS, Kreisl WC, Taku A, Fujita M, Pike WV, Innis RB: Metabotropic glutamate subtype 5 receptors are quantified in the human brain with a novel radioligand for PET. J Nucl Med 2008, 49:2042–2048.